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Abstract
Purpose:  To report our experience treating soft tissue sarcoma (STS) with high dose rate
brachytherapy alone (HBRT) or in combination with external beam radiotherapy (EBRT) in
pediatric patients.
Methods and materials: Eighteen patients, median age 11 years (range 2 – 16 years) with grade
2–3 STS were treated with HBRT using Ir-192 in a interstitial (n = 14) or intracavitary implant (n
= 4). Eight patients were treated with HBRT alone; the remaining 10 were treated with a
combination of HBRT and EBRT.
Results: After a median follow-up of 79.5 months (range 12 – 159), 14 patients were alive and
without evidence of disease (5-year overall survival rate 84.5%). There were no local or regional
failures in the group treated with HBRT alone. One patient developed distant metastases at 14
months and expired after 17 months. In the combined HBRT and EBRT group, there was 1 local
failure (22 months), and 3 patients developed pulmonary metastatic disease 18, 38 and 48 months
after diagnosis and no these patients were alive at the time of this report. The overall local control
to HBRT alone and HBRT plus EBRT were 100 and 90%, respectively. The acute affects most
common were local erythema and wound dehiscence in 6 (33%) and 4 (22%) patients.
Late effects were observed in 3 patients (16.5%).
Conclusion: Excellent local control with tolerable side effects have been observed in a small group
of paediatric patients with STS treated by HBRT alone or in combination with EBRT.
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Introduction
A variety of radiotherapeutic approaches have been used
in the adjuvant local management of soft tissue sarcoma
(STS). These include external beam irradiation (EBRT),
brachytherapy (BRT), and intraoperative radiation ther-
apy. Unfortunately, EBRT can cause growth retardation or
adversely affect organ function in the pediatric popula-
tion. Although randomized trials comparing BRT and
EBRT in STS have not been published, hypothetically,
brachytherapy offers several advantages for pediatric
patients with soft tissue sarcoma (STS) over EBRT. BRT can
reduce the dose of radiation to normal tissues and short-
ens the overall treatment time while maintaining a com-
parable high rate of local control. Thus, reductions in
normal tissue doses decrease the probability of growth
deformity, radiochemotherapy interactions, and theoreti-
cally, the rate of second tumor formation. BRT may also
allow a reduction in the EBRT dose required [1]. So, BRT
seems to be ideally suited for the pediatric patient when
used alone or in combination with EBRT to achieve local
control. Until early 90 decade, the reports enrolled
patients treated with low dose rate isotopes. The local con-
trol rates were effective, but the operational difficulties to
care children with brachytherapy sources make this
approach restricted to few institutions. The value of HBRT
for STS has been consistently demonstrated in adults with
local control advantage of BRT over wide local excision
alone for adults with high-grade tumors [1-5]. In children,
limited data are available from series that include rela-
tively small numbers of patients with different tumor
types [6-10], however the theoretical advantages of HBRT
makes this treatment modality an interesting option to
multidisciplinary management of STS. In the current
study we report our experience treating STS with HBRT in
18 patients who were submitted to BRT alone or in com-
bination with EBRT. The clinical details of these patients
and outcome are presented and discussed.
Methods and materials
Eighteen pediatric patients with STS, median age 11 years
(range 1 – 16 years), were treated with BRT between 1992
and 2004 at Hospital do Cancer A. C. Camargo. BRT was
performed in conjunction with surgery, chemotherapy
and EBRT during the initial management. Tables 1, 2, 3
contain pertinent clinical and treatment information
obtained from the medical record. To ensure accuracy in
reporting, disease status was confirmed for all patients
prior to submission of the manuscript. No one was lost to
follow up. The tumor size was determined from the gross
pathologic description when available. It was otherwise
obtained from the initial clinical description. Tumor
grade, histology subtype, and margins were obtained from
the microscopic pathologic description.
The brachytherapy procedure
BRT is the interstitial, intracavitary, or surface application
of radioisotopes in a temporary or permanent fashion. All
of the patients included in this study were treated with
temporary interstitial implants using iridium-192 HDR
microsource remote controlled by computer. Temporary
implants were performed by placing afterloading cathe-
ters into the tumor bed most commonly, and some cases,
after surgery, guide by an image procedure at the time of
resection. Two techiniques were commonly used: intrac-
Table 1: Patient and treatment summary
Patient/age Diagnosis Grade* Implant site Margins CMT Group* HDRBT 
(Gy)
EBRT 
(Gy)
Local failure Distant failure DFS 
(mo)
female/9 RMSE III Head neck Negative Yes I 18 41.4 159
female/16 Synovial sarcoma III extremity Negative None I 24 None 19
Female/2 ASPS II Extremity Negative Yes I 24 None 21
Female/14 Synovial sarcoma II Extremity Hand Positive None II 24 41.4 Lung 45
Male/5 Synovial sarcoma II Head neck Negative Yes I 24 None 79
Female/12 ASPS III Extremity Negative None I 18 30.6 29
Female/2 RMSE II Pelvic negative Yes I 24 None 54
Male/4 ASPS II Extremity Positive Yes II 24 None 143
female/1 ASPS III Extremity Positive Yes II 30 None Lung 18
Male/2 fibrosarcoma II Pelvic Negative Yes I 40 None 83
Female/11 Synovia sarcomal III Extremity Positive Yes II 24 50 141
Female/9 RMSE III Head Neck Positive Yes III 18 43.2 65
Female/12 RMSE III Head Neck positive Yes III 18 45 94
Male/2 ASPS II Pelvic Negative Yes I 21 None 12
Male/9 Synovial sarcoma II Extremity Negative Yes I 30 None 114
Female/12 RMS pleomorfic II Extremity Negative None I 21 None 80
Female/3 Sarcoma indiferency III Extremity Negative Yes I 21 41.4 Lung 38
female/16 ASPS III Extremity Positive Yes III 24 50.0 yes NCS 18
*Intergroup Rhabdomyosarcoma Study (IRS) staging used for both rhabdomyosarcomas and nonrhabdomyosarcomas. ASPS= soft tissue sarcoma 
alveolar, RMSE= Rhabdomyosarcoma embryonaryRadiation Oncology 2008, 3:9 http://www.ro-journal.com/content/3/1/9
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avitary applicators and interstitial implants. Intracavitary
brachytherapy was done by the confection of special
devices (moulds) of catheter located into the vagina,
nasopharynx and urethra, to treat of these sites. The
moulds and catheter positioning were checked with
orthogonal x-ray and the source position activated accord-
ing to the isodose optimization. In the interstitial brachy-
therapy the tumor bed was jointly outlined by the surgeon
and radiation oncologist. Permanent radiopaque clips
were placed at the margins of the tumor bed. After load-
ing, catheters were sutured into the tumor bed using chro-
mic suture. One or both ends of the afterloading catheters
were made to exit the site percutaneously at a short dis-
tance from the tumor bed. No effort was made to cover the
wound or drain sites. In general, the catheters extended
within the treatment plane 2 cm beyond the extent of the
tumor bed. On the first postoperative day orthogonal
plain-films were taken and the dosimetry of the treatment
determined. The isotope and dose rates were selected to
deliver 600 – 1000 cGy per day in two fraction eight hours
between applications, with a minimum distance of 0.5 cm
beyond the plane(s) of the implant. Dose distributions
were calculated in multiple planes at 0.5- or 1.0-cm inter-
vals that were roughly perpendicular to the ribbons. The
highest dose rate for which the isodose contour was con-
tinuous and covers the CTV was selected as the prescrip-
tion dose rate.
The dose rates were selected according to age, anatomic
site and EBRT total dose received. The duration of the
implant depended on the use of BRT as the only radiation
modality or as a boost supplement to EBRT. BRT alone
was generally used when tumor resection was complete
with negative margins. The combination of EBRT and BRT
was used for patients with involved margins. The mean
number of catheters used per site was 6 (range 2–11) to
cover a mean target volume of 59.7 cm3 (range 21 – 126).
Statistical Analysis
Local failure was defined as tumor progression within the
BRT volume. Regional failure was defined as tumor pro-
gression adjacent to and outside of the BRT or EBRT vol-
ume in the same organ or structure. Distant failure was
defined as tumor progression in a previously noninvolved
organ or structure. Overall survival was measured from
the date of diagnosis. Disease-free survival was measured
from the completion of radiation therapy, confirmed by
biopsy or image exam. Kaplan-Meier method was used for
survival analysis.
Results
After a median follow-up of 79.5 months (range 12 –
159), 14 patients were alive and without evidence of dis-
ease. Overall survival rates at 5-year and 10-year was
84.4% and 72.4%, figure 1. 18 patients were initially
Table 2: Local control, distant failure, and survival rates according to margin, chemotherapy and treatment modality.
Local control (%) Distant failure (%) Overall survival (%)
Overall 94.5 (17/18) 22 (4/18) 78 (14/18)
Margins
Negative 100 (11/11) 1 (1/11) 91 (10/11)
Positive 85.7 (6/7) 42.8(3/7) 57.1 (3/7)
Neoadjuvant chemotherapy
Yes 92.8 (13/14) 21.4(3/14) 78.5(11/14)
No 100(4/4) 25(1/4) 75 (3/4)
Treatment modality
BRT alone 100 (8/8) 25 (2/8) 25 (2/8)
BRT+EBRT 90 (1/10) 20 (2/10) 20 (2/10)
Table 3: Institutional results for brachytherapy in pediatric tumors
Center Patients (n) Brachytherapy LCR (%)
St. Jude Children's Research Hospital (8) 46 LDR 86
University of Southern California (17) 8L D R 6 3
Joint Center for Radiation Therapy (18) 7 LDR (125Ir) 100
Austrian data (16) 12 Fract-HDR 75
Ohio State University (14) 12 Fract-HDR 91
Ohio State University (21) 13 IO-HDR 95
Memorial Sloan-Kettering Hospital (15) 10 IO-HDR 80
Present study A.C. Camargo, Brazil 18 Fract-HDR 94.5Radiation Oncology 2008, 3:9 http://www.ro-journal.com/content/3/1/9
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managed with HBRT; HBRT alone was performed in 10 of
these patients and the remainders were treated with a
combination of HBRT and EBRT. The most common his-
tologic subtypes include alveolar soft part sarcoma (n =
6), synovial cell sarcoma (n = 5), rhabdomyosarcoma
embryonary (n = 5), fibrosarcoma (n = 1), indifference
sarcoma (n = 1). All patients had intermediate to high
grade tumors and most (n = 11) had no involved margins
of resection at the time that HBRT was performed. intrac-
avitary brachytherapy was done in 4 patients follow as:
one vaginal, one urethral and two nasopharynx sites.
There were no local or regional failures in the group
treated with HBRT alone. One patient developed distant
metastases at 45 months and expired after 85 months.
Fourteen patients were alive with no evidence of disease
12, 19, 21, 29, 43, 56, 65, 79, 80, 83, 85, 94, 143 and 159
months after diagnosis. In the combined HBRT and EBRT
group, there was 1 local failure (22 months), and 3
patients developed pulmonary metastatic disease 18, 38
and 45 months after diagnosis. The patients who pre-
sented with or who developed lung metastases were
treated with pulmonary metastasectomy; no patients were
alive at the time of this report. All patients died, including
one of the 4 patients in this group who presented with
nervous central system metastatic disease (table 1). Dis-
ease free survival at 5 was 72.4%, figure 2. The overall
local control was 94.5% at time this report, in the group
that was submitted to HBRT alone and HBRT plus EBRT
local control was 100 and 90%, respectively. Patients who
had gross total tumor resection without compromising of
the margins had better local control compared to patients
with positive margins (100% vs 85%), showed in table 2.
The acute affects most common were local erythema
present in 6 (33%) patients and wound dehiscence that
occurred in 4 (22%) patients. Late effects were observed in
3 patients (16.5%). One 2-year old child with a vaginal
rhabdomyosarcoma embrionary who received 24 Gy of
HBRT and perioperative chemotherapy developed vaginal
introitum stenosis, and corrected by genitoplasty proce-
dure two years later. Another patient male of 11 years old
with a synovial sarcoma in poplitea fossa who received.
HBRT with dose of 24 Gy and EBRT 50 Gy and periopera-
tive chemotherapy, three years later developed muscle
atrophy in the volume treated. A third patient male with 5
years old had a head neck synovial sarcoma and was
treated by HBRT with dose of 24 Gy, one year later he
developed dyschromy and teleangiectasy in area treated.
Discussion
BRT may be used to deliver high doses of radiation in a
localized volume, thereby reducing the probability of
radiation-related side effects that are likely to occur when
children are treated with external beam irradiation. The
dose required to control STS exceeds that prescribed for
the more common pediatric solid tumors which makes it
more imperative that measures be taken to minimize the
toxicity of radiation therapy and preserve function with-
out compromising local control or overall survival.
In this context from 1982 we start to use BRT on manage-
ment of STS, achieving satisfactory local control rate [11].
The introduction of HBRT on clinical practice makes this
approach the preferential option to children brachyther-
apy after 1992 in our institution.
Hypothetically, fractionated HRBT combines the tissue-
sparing, dosimetric advantages of brachytherapy treat-
Disease Free Survival for patients with STS treated with  EBRT+-BRT Figure 2
Disease Free Survival for patients with STS treated 
with EBRT+-BRT.
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ment and the radiobiologic advantages of fractionation.
Fractionated HRBT allows for reoxygenation and redistri-
bution of residual cancer cells by delivering 300 cGy frac-
tions twice daily to a total dose of 36 Gy during 8 days
[12,13]. Repopulation is limited, because the RT is started
within days of surgery and delivered through catheters
implanted during surgery. At our institution, fractionated
HBRT alone is reserved for those patients with limited vol-
ume disease, tumors with margins of resection negative.
Patients with positive margins after ressection, high grade
tumors, HBRT associated EBRT is used. Potter et al. [14]
described their experience with fractionated HRBT in 12
children with primary and recurrent soft-tissue sarcomas,
7 of whom received HRBT as their sole treatment. The rate
of local control and 2-year overall survival was 75% and
65%, respectively, with no significant morbidity [14]. Nag
et al. [13] reported a 6-year actuarial local control rate of
91% and an overall survival rate of 81% in 12 children.
Subcutaneous fibrosis and delayed dentition were noted
in 2 of the children. Low-dose-rate brachytherapy (LBRT)
has many advantages and is commonly used in adults for
the treatment of soft-tissue sarcomas and other cancers.
However, LBRT is difficult to administer in the pediatric
population because of compliance issues and the poten-
tial radiation exposure to the caregivers. St. Jude Chil-
dren's Hospital reported the use of LRBT alone or in
combination with EBRT (range 12–60 Gy) in 46 patients
with non-central nervous system malignancies [8]. Ours
data are according to other series of the literature, table 3
lists the largest series to date dealing with brachytherapy
in the pediatric population [8,13-17]. Parameters that are
important to consider in choosing the appropriate intra-
operative or perioperative technique include the presence
of gross versus microscopic disease, the size and accessi-
bility of the treatment volume, the position of adjacent
critical structures, whether EBRT was previously given,
and whether postoperative EBRT is planned. We use BRT
combined with external beam irradiation for high-grade
and intermediate-grade tumors with involved, inade-
quate, or indeterminate margins regardless of size or ana-
tomic location. Low-grade tumors are treated with BRT
only when the risk of recurrence and re-resection morbid-
ity is high or at the time or recurrence.
High-grade adult tumors of all sizes treated with BRT
alone have improved local control over those who receive
no BRT when the tumor is grossly excised with or without
involved margins [5]. There is a suggestion that adult
patients with involved margins have a high probability of
local control when treated with combined BRT and exter-
nal beam irradiation compared to implant alone [1].
Tumor size and anatomic location have been debated as
important factors to be used to guide decisions regarding
the use of radiation therapy. Identifying prognostic factors
and the relative indications for radiation therapy of STS in
the pediatric population has been difficult to determine
because of the histologic diversity and biology of these
tumors and to identify subsets of patients who would not
require irradiation and who would not be subjected to the
long-term morbidity of irradiation. We have received chil-
dren with tumors generally smaller than those found in
adults, that wide local excision likely produced substan-
tial morbidity, in this way wide local excision is often not
possible, because these patients often lack subcutaneous
tissue. Further, patients are commonly referred to our
institution following limited, non oncologic resection in
the community which further confounds our ability to
differentiate or identify patients who may be treated with
surgery alone. In these cases BRT alone or in combination
EBRT may be used to deliver high doses of radiation in a
localized volume, thereby reducing the probability of
radiation-related side effects. It is difficult to retrospec-
tively evaluate the impact of HBRT on structure and func-
tion. The rate of complication, both acute and chronic,
ranges from 10–48% depending on the series [18,19]. In
our patients, 4 suffered wound dehiscence after HBRT;
one received preimplant EBRT, the other three were
treated with chemotherapy in the perioperative period.
The most common side effects of HBRT were radiation
local erythema, teleangiectasy and fibrosis that are likely
to occur when children are treated with external beam
irradiation alone.
In conclusion, excellent local control with tolerable side
effects have been observed in a small group of paediatric
patients with STS treated by HBRT alone or in combina-
tion with EBRT. Younger patients with STS may achieve
local control and prevent growth retardation with a com-
bination of BRT and moderate doses of EBRT. Longer fol-
low-up is required to determine the full extent of late
effects. Limb preservation, functional outcome, and toxic-
ity assessment require careful assessment in a prospective
study.
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